Haldol Decanoas

Haldol Decanoas is a pharmaceutical product containing the active ingredient haloperidol decanoate, supplied as an intramuscular injection. The formulation is a long‑acting butyrophenone antipsychotic used in the European market. It is a prescription‑only medication that delivers haloperidol in a depot form for sustained plasma levels. It is indicated for the management of schizophrenia and other chronic psychotic conditions, and may be administered by a healthcare professional in a clinical setting.

Haloperidol decanoate is prescribed for several psychiatric indications where long‑term control of psychotic symptoms is required. - Maintenance therapy for adult patients with schizophrenia to reduce relapse risk and improve adherence. - Management of acute psychotic episodes when a rapid, sustained antipsychotic effect is desired. - Adjunctive use in schizoaffective disorder as part of a comprehensive treatment plan. - Long‑acting depot option for individuals who have difficulty adhering to daily oral antipsychotics. - Prevention of symptom recurrence in chronic psychotic disorders such as bipolar disorder with psychotic features. - Transition support when switching from oral haloperidol to a depot formulation, often combined with short‑term oral coverage.

Side effects of haloperidol decanoate reflect its dopamine D2 antagonism and can be grouped into common and serious categories.

Common: - Extrapyramidal symptoms such as tremor, rigidity, or akathisia - Sedation or drowsiness - Dry mouth and constipation - Elevated prolactin levels leading to menstrual changes or galactorrhea

Serious: - Tardive dyskinesia, a potentially irreversible movement disorder - Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability - Cardiac arrhythmias, including QT interval prolongation

Before initiating haloperidol decanoate, clinicians should evaluate several safety considerations and patient‑specific factors. - Assess for a history of cardiovascular disease, arrhythmias, or prolonged QT interval. - Evaluate the risk of extrapyramidal symptoms, especially in patients with Parkinson’s disease or prior EPS. - Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation. - Consider pregnancy and lactation status; safety data are limited, and risks should be weighed. - Review liver and renal function, as impairment may affect drug metabolism and clearance. - Use caution in patients with diabetes or metabolic syndrome due to possible hyperglycemia.

Haloperidol decanoate can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use with other strong dopamine antagonists, which may increase the risk of severe extrapyramidal symptoms. - Co‑administration with medications that markedly prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.

Use with caution: - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may raise haloperidol levels; dose adjustment may be needed. - CYP3A4 inducers (e.g., carbamazepine, rifampin) can reduce plasma concentrations, potentially diminishing efficacy. - CNS depressants, including benzodiazepines or alcohol, may enhance sedation. - Anticholinergic agents may mask early signs of extrapyramidal side effects.